Dietary energy balance modulation of Kras- and Ink4a/Arf +/--driven pancreatic cancer: The role of insulin-like growth factor-I

Cancer Prevention Research

Volumn 6, Issue 10, 2013, Pages 1046-1055

  Lashinger, Laura M ^a   Harrison, Lauren M ^a   Rasmussen, Audrey J ^a   Logsdon, Craig D ^b   Fischer, Susan M ^c   McArthur, Mark J ^c,d   Hursting, Stephen D ^a,c  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UT MDACC   (United States)

^d Department of Veterinary Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALORIC RESTRICTION; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DIETARY ENERGY BALANCE MODULATION; DISEASE COURSE; ENERGY BALANCE; MALE; METABOLIC REGULATION; MOUSE; NONHUMAN; OBESITY; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION;

ANIMALS; BLOOD GLUCOSE; BODY COMPOSITION; CALORIC RESTRICTION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE-FREE SURVIVAL; ENERGY METABOLISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR I; LIVER; MALE; MICE; MICE, TRANSGENIC; MUTATION; NEOPLASM TRANSPLANTATION; OBESITY; PANCREATIC NEOPLASMS; PHENOTYPE; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84887949665     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0185     Document Type: Article

References (31)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Lillemoe KD, Yeo CJ, Cameron JL. Pancreatic cancer: state-of-the-art care. CA Cancer J Clin 2000;50:241-68. (Pubitemid 30654881)
3. Maitra A, Kern SE, Hruban RH. Molecular pathogenesis of pancreatic cancer. Best Pract Res Clin Gastroenterol 2006;20:211-26.
4. Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res 2000;6:2969-72. (Pubitemid 30637716)
5. Calle EE, Rodriguez C, Jacobs EJ, Almon ML, Chao A, McCullough ML, et al. The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics. Cancer 2002;94:500-11. (Pubitemid 34081382)
6. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-38. (Pubitemid 36459468)
7. Calle EE, Thun MJ. Obesity and cancer. Oncogene 2004;23:6365-78. (Pubitemid 39265505)
8. Patel AV, Rodriguez C, Bernstein L, Chao A, Thun MJ, Calle EE. Obesity, recreational physical activity, and risk of pancreatic cancer in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 2005;14: 459-66. (Pubitemid 40270112)
9. Nothlings U, Wilkens LR, Murphy SP, Hankin JH, Henderson BE, Kolonel LN. Body mass index and physical activity as risk factors for pancreatic cancer: the Multiethnic Cohort Study. Cancer Causes Control 2007;18:165 -75.
10. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012;307:491-7.
11. Matrisian LM AR, Rosenzweig A. The alarming rise of pancreatic cancer deaths in the United States: why we need to stem the tide today. 2012 [cited 2013]. Available from: http://www.pancan.org/section-research/reports/incidence- report.php].
12. Hursting SD, Digiovanni J, Dannenberg AJ, Azrad M, Leroith D, Demark-Wahnefried W, et al. Obesity, energy balance, and cancer: new opportunities for prevention. Cancer Prev Res 2012;5:1260-72.
13. Moore T, Beltran L, Carbajal S, Strom S, Traag J, Hursting SD, et al. Dietary energy balance modulates signaling through the Akt/mammalian target of rapamycin pathways in multiple epithelial tissues. Cancer Prev Res 2008;1:65-76.
14. Blando J, Moore T, Hursting S, Jiang G, Saha A, Beltran L, et al. Dietary energy balance modulates prostate cancer progression in Hi-Myc mice. Cancer Prev Res 2011;4:2002-14.
15. Ford NA, Nunez NP, Holcomb VB, Hursting SD. IGF1 dependence of dietary energy balance effects on murine Met1 mammary tumor progression, epithelial-to-mesenchymal transition, and chemokine expression. Endocr Relat Cancer 2013;20:39-51.
16. Nunez NP, Perkins SN, Smith NC, Berrigan D, Berendes DM, Varticovski L, et al. Obesity accelerates mouse mammary tumor growth in the absence of ovarian hormones. Nutr Cancer 2008;60:534-41. (Pubitemid 351918549)
17. Hori M, Kitahashi T, Imai T, Ishigamori R, Takasu S, Mutoh M, et al. Enhancement of carcinogenesis and fatty infiltration in the pancreas in N-nitrosobis(2-oxopropyl)amine-treated hamsters by high-fat diet. Pancreas 2011;40:1234-40.
18. Zyromski NJ, Mathur A, Pitt HA, Wade TE, Wang S, Nakshatri P, et al. Obesity potentiates the growth and dissemination of pancreatic cancer. Surgery 2009;146:258-63.
19. White PB, Ziegler KM, Swartz-Basile DA, Wang SS, Lillemoe KD, Pitt HA, et al. Obesity, but not high-fat diet, promotes murine pancreatic cancer growth. J Gastrointest Surg 2012;16:1680-5.
20. Khasawneh J, Schulz MD, Walch A, Rozman J, Hrabe de Angelis M, Klingenspor M, et al. Inflammation and mitochondrial fatty acid beta-oxidation link obesity to early tumor promotion. Proc Natl Acad Sci U S A 2009;106:3354-9.
21. Hursting SD, Lavigne JA, Berrigan D, Perkins SN, Barrett JC. Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. Annu Rev Med 2003;54:131-52. (Pubitemid 37386388)
22. Lashinger LM, Malone LM, Brown GW, Daniels EA, Goldberg JA, Otto G, et al. Rapamycin partially mimics the anticancer effects of calorie restriction in a murine model of pancreatic cancer. Cancer Prev Res 2011;4:1041-51.
23. Lashinger LM, Malone LM, McArthur MJ, Goldberg JA, Daniels EA, Pavone A, et al. Genetic reduction of insulin-like growth factor-1 mimics the anticancer effects of calorie restriction on cyclooxy-genase-2-driven pancreatic neoplasia. Cancer Prev Res 2011;4: 1030-40.
24. Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, et al. Activated Kras and Ink4a/Arf defi ciency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 2003;17: 3112-26. (Pubitemid 38040774)
25. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U S A 1999;96:7324-9. (Pubitemid 29299660)
26. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002;2:897-909. (Pubitemid 37328891)
27. Moore T, Carbajal S, Beltran L, Perkins SN, Yakar S, Leroith D, et al. Reduced susceptibility to two-stage skin carcinogenesis in mice with low circulating insulin-like growth factor I levels. Cancer Res 2008;68: 3680-8.
28. Hursting SD, Switzer BR, French JE, Kari FW. The growth hormone: insulin-like growth factor 1 axis is a mediator of diet restriction-induced inhibition of mononuclear cell leukemia in Fischer rats. Cancer Res 1993;53:2750-7. (Pubitemid 23180510)
29. Dunn SE, Kari FW, French J, Leininger JR, Travlos G, Wilson R, et al. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res 1997;57:4667-72. (Pubitemid 27468963)
30. Tao R, Acquati F, Marcovina SM, Hobbs HH. Human growth hormone increases apo(a) expression in transgenic mice. Arterioscler Thromb Vasc Biol 1999;19:2439-47. (Pubitemid 29477846)
31. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012;12:159-69.